187 related articles for article (PubMed ID: 21190026)
1. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab.
Odom D; Barber B; Bennett L; Peeters M; Zhao Z; Kaye J; Wolf M; Wiezorek J
Int J Colorectal Dis; 2011 Feb; 26(2):173-81. PubMed ID: 21190026
[TBL] [Abstract][Full Text] [Related]
2. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
Kim TW; Elme A; Kusic Z; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Bilic A; Manojlovic N; Dong J; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Br J Cancer; 2016 Nov; 115(10):1206-1214. PubMed ID: 27736842
[TBL] [Abstract][Full Text] [Related]
3. A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.
Wang J; Zhao Z; Barber B; Sherrill B; Peeters M; Wiezorek J
Br J Cancer; 2011 Jun; 104(12):1848-53. PubMed ID: 21610704
[TBL] [Abstract][Full Text] [Related]
4. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Amado RG; Wolf M; Peeters M; Van Cutsem E; Siena S; Freeman DJ; Juan T; Sikorski R; Suggs S; Radinsky R; Patterson SD; Chang DD
J Clin Oncol; 2008 Apr; 26(10):1626-34. PubMed ID: 18316791
[TBL] [Abstract][Full Text] [Related]
5. Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
Weber J; McCormack PL
BioDrugs; 2008; 22(6):403-11. PubMed ID: 18998757
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
7. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
8. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
Oncologist; 2012; 17(1):14. PubMed ID: 22210091
[TBL] [Abstract][Full Text] [Related]
9. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
10. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
[TBL] [Abstract][Full Text] [Related]
12. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
Graham CN; Maglinte GA; Schwartzberg LS; Price TJ; Knox HN; Hechmati G; Hjelmgren J; Barber B; Fakih MG
Clin Ther; 2016 Jun; 38(6):1376-1391. PubMed ID: 27085587
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment.
Bennett L; Zhao Z; Barber B; Zhou X; Peeters M; Zhang J; Xu F; Wiezorek J; Douillard JY
Br J Cancer; 2011 Nov; 105(10):1495-502. PubMed ID: 21989186
[TBL] [Abstract][Full Text] [Related]
14. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
Au HJ; Karapetis CS; O'Callaghan CJ; Tu D; Moore MJ; Zalcberg JR; Kennecke H; Shapiro JD; Koski S; Pavlakis N; Charpentier D; Wyld D; Jefford M; Knight GJ; Magoski NM; Brundage MD; Jonker DJ
J Clin Oncol; 2009 Apr; 27(11):1822-8. PubMed ID: 19273701
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
17. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
Siena S; Peeters M; Van Cutsem E; Humblet Y; Conte P; Bajetta E; Comandini D; Bodoky G; Van Hazel G; Salek T; Wolf M; Devercelli G; Woolley M; Amado RG
Br J Cancer; 2007 Dec; 97(11):1469-74. PubMed ID: 18040272
[TBL] [Abstract][Full Text] [Related]
18. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.
Sastre J; Massuti B; Pulido G; Guillén-Ponce C; Benavides M; Manzano JL; Reboredo M; Rivera F; Grávalos C; Safont MJ; Martínez Villacampa M; Llovet P; Dotor E; Díaz-Rubio E; Aranda E;
Eur J Cancer; 2015 Jul; 51(11):1371-80. PubMed ID: 25963019
[TBL] [Abstract][Full Text] [Related]
19. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab: a review of its use in metastatic colorectal cancer.
Keating GM
Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
